Clinical Trial Update: A Crossover Study to Evaluate the Safety, Tolerability and Efficacy of XPF-002 in Subjects With Postherpetic Neuralgia (PHN) [Phase 2]

View source ↗

Summary

Phase 2 crossover study evaluating XPF-002 for postherpetic neuralgia. Results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Postherpetic Neuralgia

Drugs mentioned

• XPF-002

Snippet

Sponsor: Xenon Pharmaceuticals Inc. | Conditions: Postherpetic Neuralgia | Phase 2 | Status: COMPLETED | Results posted: 2013-11-25